Company Monitoring Page for Regeneron

job ratings for Regeneron

12/30/22
industry:
Big Pharma
company:
Regeneron
job rating:
1
My boss is abusive
10/21/17
industry:
Bio-Tech
job title:
Medical Specialist Immunology
company:
Regeneron
job rating:
7
Best company I’ve ever worked for. Best DM, best upper management, focus strongly on older, successful reps.
06/06/17
industry:
Bio pharmaceutical Industry
company:
Regeneron
job rating:
5
I have lived my job until lately. We are being forced to become Moreno like Sanofi. I now want to leave my job and go elsewhere because of it.
05/29/17
industry:
pharma
company:
Regeneron
job rating:
1
culture
01/29/17
industry:
Biotechnology
company:
Regeneron
job rating:
7
Transparency is great! pay is decent. Bonus opportunity is good.

latest headlines for company on cafepharma

FDA Decisions 2023: Sandoz, Gilead Sciences and More
BioSpace
Fri, 08/25/23 - 11:31 am
Tags:
FDA, Sandoz, Novartis, Gilead Sciences, Pfizer, Neurocrine, Regeneron, Ipsen, Revance Therapeutics, Delcath Systems, Janssen, Galera Therapeutics, Biogen, Roche, Mesoblast, Taiho Oncology
Regeneron, J&J Win HHS Funding to Develop Next-Gen COVID Products
BioSpace
Wed, 08/23/23 - 09:54 am
Tags:
HHS, Regeneron, JNJ, COVID-19, funding
Regeneron Expands Eylea’s Label with High-Dose Approval
BioSpace
Mon, 08/21/23 - 10:44 am
Tags:
Regeneron, Eylea, FDA
Regeneron’s Antibody Gets FDA Approval for Ultra-Rare Hereditary Disease
BioSpace
Sun, 08/20/23 - 05:17 pm
Tags:
Regeneron, FDA, CHAPLE disease, Veopoz
FDA Action Alert: Ipsen, Revance, Neurocrine and Regeneron
BioSpace
Mon, 08/14/23 - 11:29 am
Tags:
FDA, Ipsen, Revance Therapeutics, Neurocrine, Regeneron, palovarotene, fibrodysplasia ossificans progressiva, Daxxify, cervical dystonia, Ingrezza, chorea, Huntington's disease, pozelimab, CHAPLE disease
Regeneron's high-dose Eylea shows staying power as company awaits FDA decision
Fierce Pharma
Thu, 08/10/23 - 09:49 pm
Tags:
Regeneron, Eylea, age-related macular degeneration, FDA
Regeneron adds Decibel to gene therapy playlist, turning up volume on long-running hearing loss collaboration
Fierce Biotech
Wed, 08/9/23 - 10:10 am
Tags:
Regeneron, hearing loss, Decibel Therapeutics, gene therapy, M&A
Regeneron expects FDA decision on higher-dose Eylea this year
Reuters
Thu, 08/3/23 - 06:40 pm
Tags:
Regeneron, Eylea, FDA
Moderna, Regeneron post solid earnings, eye a strong finish to 2023
Medical Marketing and Media
Thu, 08/3/23 - 11:23 am
Tags:
earnings, Moderna Therapeutics, Regeneron
Regeneron rethinks CD28 bispecific R&D plan after 2 patients die
Fierce Biotech
Thu, 08/3/23 - 10:17 am
Tags:
Regeneron, prostate cancer, clinical trials, patient deaths, REGN5678, bispecific antibodies
5 Highly Anticipated FDA Decisions for Rare Diseases Coming This Year
BioSpace
Fri, 07/28/23 - 11:46 am
Tags:
Ipsen, palovarotene, fibrodysplasia ossificans progressiva, Regeneron, CHAPLE disease, pozelimab, Biomarin, Voxzogo, achondroplasia, Santhera Pharmaceuticals, vamorolone, DMD, Springworks, nirogacestat, desmoid tumors
Scratching the surface of the urticaria pipeline
EP Vantage
Thu, 07/20/23 - 10:00 am
Tags:
chronic urticaria, Sanofi, Dupixent, Regeneron, Novartis, Roche, Xolair, Allakos, AstraZeneca, Celldex Therapeutics
Dupixent goes back-to-back as top Rx, OTC pharma brand in June
Medical Marketing and Media
Thu, 07/6/23 - 10:16 am
Tags:
Dupixent, Sanofi, Regeneron
Is Regeneron's Stock in Trouble After This FDA Rejection?
Motley Fool
Thu, 07/6/23 - 10:15 am
Tags:
Regeneron, Eylea, FDA
Regeneron's high-dose Eylea hit with surprise FDA rejection over manufacturing hiccups
Fierce Pharma
Tue, 06/27/23 - 10:24 pm
Tags:
Regeneron, Eylea, FDA
Aslan sells Japanese rights to would-be Dupixent rival for $12M
Fierce Biotech
Thu, 06/22/23 - 10:41 pm
Tags:
Aslan, Dupixent, Japan, eczema, Sanofi, Regeneron, eblasakimab
Dupixent reclaims throne as top Rx, OTC pharma brand in May
Medical Marketing and Media
Tue, 06/6/23 - 11:13 am
Tags:
Dupixent, Sanofi, Regeneron, DTC advertising
Go or no go? Key FDA decisions for Argenx and Regeneron
EP Vantage
Wed, 05/31/23 - 10:51 am
Tags:
FDA, Albireo Pharma, Aldeyra Therapeutics, Alvotech, Amneal Pharmaceuticals, Argenx, ARS Pharmaceuticals, AstraZeneca, Bayer, Bio-Thera Solutions, Biogen, BioMarin Pharmaceutical, Bristol Myers Squibb, Eisai, Eton Pharmaceuticals, F2G, Fabre-Kramer Pharmaceuticals, Fresenius, GSK, Intercept Pharmaceuticals, Ipsen, Ironwood Pharmaceuticals, Merck, Novaliq, Pfizer, Regeneron, Roche, Sanofi, Sarepta Therapeutics, Shionogi, Swedish Orphan Biovitrum, Takeda, Teva Pharmaceutica, UCB Pharma
ASCO: Regeneron's Opdualag rival records double the historical response rate in melanoma
Fierce Biotech
Thu, 05/25/23 - 08:49 pm
Tags:
ASCO 2023, Regeneron, advanced melanoma, fianlimab
Sanofi, Regeneron flesh out COPD data with Dupixent
Pharmaphorum
Mon, 05/22/23 - 10:16 am
Tags:
Sanofi, Regeneron, COPD, Dupixent

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.